FDA Approves OraSure's In-Home HIV Test; Abbott Receives FDA Approval for Healon EndoCoat Print E-mail
By Staff and Wire Reports   
Tuesday, 03 July 2012 18:25
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 3, 2012.

OraSure Technologies, Inc. (Nasdaq: OSUR)
announced the U.S. FDA has approved the Company's OraQuick® In-Home HIV Test for sale directly to consumers in the over-the-counter (OTC) market – making it the first and only rapid OTC HIV test approved in the U.S. The OraQuick® In-Home HIV Test can detect antibodies to both HIV-1 and HIV-2 with an oral swab, providing a confidential in-home testing option with results in as little as 20 minutes. It is the first rapid diagnostic test for any infectious disease that has been approved by the FDA for sale over the counter.


Abbott Laboratories (NYSE:ABT) announced it has expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) with the U.S. Food and Drug Administration approval of Healon EndoCoat OVD, a device intended for use as a surgical aid in cataract extraction and intraocular lens (IOL) implantation.

This clear, viscous, protective gel formula is injected into a patient's eye to protect and coat the eye during surgery, reducing trauma to the inside layer of the cornea and other surrounding tissues.

The surgical delivery system for Healon EndoCoat OVD includes a number of features for increased patient safety and ease of handling for the physician, including a smaller delivery device and improved ergonomics for a smooth and consistent delivery of the formula into the eye.

Also Tuesday:

Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE)
, a biopharmaceutical company conducting clinical trials on its four lead drugs (Ampion™, Optina™, Zertane™ & Zertane-ED™) licensing distribution of these drugs and developing additional new drugs, announced today that Dr. David Bar-Or, Ampio's Founder, Chief Scientific Officer and largest shareholder, and Michael Macaluso, Ampio's CEO, Chairman and Lead Investor, have extended their July 15th 2012 lock-up agreement until January of 2013.

Array BioPharma Inc. (Nasdaq: ARRY)
today announced that its Chief Executive Officer, Ron Squarer, will speak at the JMP Securities Healthcare Conference 2012 in New York City.

BioNeutral Group, Inc. (OTCBB: BONU)
a specialty life science technology based company announced today that it has contracted Battelle to test its Ygiene Sterilants against Bacillus anthracis Ames Spores.

China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP)
("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines ("TCM") in China, today announced that the Company's Siberian Ginseng Extract was recognized as Safe Medicine at the 8th session of the Selection Event, hosted by the Health Newspaper in China and supported by the Ministry of Health of China.

announced today that it expects to report second quarter 2012 financial results before the market opens on Thursday, July 26, 2012, and will also hold a conference call live over the Internet at 10:00 a.m. Eastern Time that same day.

On behalf of Saneron CCEL Therapeutics, Inc., President and COO, Nicole Kuzmin-Nichols, MBA, expressed strong support today for the Cryo-Cell International, Inc. (OTCQB: CCEL) current executive management in response to a proxy bid by a former Board member.

Dendreon Corporation (NASDAQ: DNDN)
today announced that John H. Johnson, president and chief executive officer, has assumed the additional title of Chairman of the Board, as of July 1, 2012.

ERT (Nasdaq: ERT)
, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations (CROs), announced today that Genstar Capital, LLC, has completed its acquisition of the company in a take-private transaction valued at approximately $400 million.

InVivo Therapeutics Holdings Corp. (OTC:NVIV)
, a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced the inaugural Langer Summit on Neurotrauma being held in North Falmouth, MA from July 6 – 8, 2012.

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)
will present at the Seventh Annual JMP Securities Healthcare Conference in New York on Thursday, July 12, 2012 at 1:30 p.m. ET.

Pressure BioSciences, Inc. (OTCQB: PBIO)
("PBI" or the "Company") today announced that it has reached agreement with seventeen investors on an initial tranche of approximately $600,000 of a $1.2 million private placement.

Santarus, Inc. (NASDAQ: SNTS)
today announced that Gerald T. Proehl, president and chief executive officer, will make a presentation at the Seventh Annual JMP Securities Healthcare Conference on Thursday, July 12, 2012, at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) in New York City.

SpectraScience, Inc. (OTCQB: SCIE) (PINKSHEETS: SCIE)
, a San Diego based medical device company, today announced that it will hold a conference call on Monday, July 9, 2012 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to provide an update on its business and conduct a question and answer session with investors.

Spectrum Pharmaceuticals (NasdaqGS: SPPI)
, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced the initiation of an international, randomized, placebo-controlled Phase 2 study evaluating lucanthone in primary therapy for Glioblastoma Multiforme (GBM).

ViroPharma Incorporated (Nasdaq: VPHM)
today announced that Colin Broom, MD, vice president and chief scientific officer of ViroPharma, will present at the 2012 JMP Securities Healthcare Conference at 11:00 A.M. ET on Thursday, July 12, 2012.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus